ALL
From the Journals
CD123 may be a marker for residual disease and response evaluation in AML and B-ALL
From the Journals
Secondary acute lymphoblastic leukemia more lethal than de novo
From the Journals
COVID-19: Adjusting practice in acute leukemia care
Conference Coverage
Second transplant a good salvage option for children with ALL, AML, or MDS
Movers in Medicine
Researchers honored by ACS, IASLC
Conference Coverage
Phase 2 data: Inotuzumab, approved in adults with B-ALL, shows promise in kids, too
“Importantly, there were no inotuzumab dose modifications or delays due to hepatic toxicity.”
Latest News
Phase 2 study shows regimen benefit with dasatinib in Ph+ALL therapy
Conference Coverage
UKALL14: Rituximab improves EFS in B-ALL, but four doses not enough
Rituximab may improve EFS in B-ALL regardless of Philadelphia chromosome status and CD20-positive expression level.
Conference Coverage
Promising early efficacy of venetoclax/navitoclax in r/r acute lymphoblastic leukemia
ORLANDO – Combining the BCL-2 inhibitor venetoclax with low-dose navitoclax produced good response rates in heavily pretreated patients with B-...
Conference Coverage
Chemo-free induction-consolidation protocol for Ph+ ALL improved survival
ORLANDO – A front-line chemo-free induction-consolidation protocol for Ph+ ALL resulted in high survival and molecular response rates in the phase...
Conference Coverage
High response, survival rates with ponatinib/hCVAD in Ph-positive ALL
ORLANDO – The third-generation tyrosine kinase inhibitor ponatinib is active against Philadelphia chromosome–positive ALL with the T315I mutation...